2024 World Conference on Lung Cancer (WCLC) - Posters-P3.08F.04 Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer: An Update on the VIGILANCE Study

P3.08F.04 Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer: An Update on the VIGILANCE Study

Back to course

Pdf Summary

The VIGILANCE study, conducted by the University of Manchester and The Christie NHS Foundation Trust, aims to improve treatment outcomes for patients with inoperable stage III non-small cell lung cancer (NSCLC) by developing personalized radiotherapy approaches using circulating and imaging biomarkers. Given the poor prognosis currently associated with this cancer stage, the study addresses the critical need for biomarkers that can inform individualized treatment decisions.<br /><br />Eligible participants include those planned for treatment with either radical radiotherapy, sequential chemoradiotherapy, or concurrent chemoradiotherapy with or without consolidation immunotherapy. The study involves collecting additional blood samples and electronic patient-reported outcome measures (ePROMs) beyond standard imaging procedures.<br /><br />Recruitment for the study commenced on March 24, 2023, and will continue for 18 months, targeting the enrollment of up to 80 patients. As of June 14, 2024, the project's progress includes prospective data collection within a homogenous patient group, employing novel biomarker technologies through a unique multi-omics approach. This design enables a rich data set, including longitudinal follow-up and patient-reported outcomes.<br /><br />The primary aim of VIGILANCE is constructing a prognostic model using baseline and longitudinal circulating-tumor DNA, radiomic features, and patient-reported measures to predict survival, tumor control, and early relapse. Secondary outcomes include the longitudinal profiling of circulating-tumor DNA and radiomic features over up to one year post-radiotherapy, alongside exploring predictive models to assess the benefit of consolidation immunotherapy. The study also seeks to identify associations between biomarker changes over time.<br /><br />Supported by Cancer Research UK, Rosetrees Trust, and AstraZeneca, this research promises to advance the understanding of personalized treatment responses in stage III NSCLC, possibly leading to improved patient outcomes.

Asset Subtitle

Ashley Horne

Meta Tag

Speaker Ashley Horne

Topic Local-Regional NSCLC

Keywords

VIGILANCE study

University of Manchester

Christie NHS Foundation Trust

non-small cell lung cancer

personalized radiotherapy

circulating biomarkers

imaging biomarkers

prognostic model

consolidation immunotherapy

Cancer Research UK